Gilead Begins Remdesivir Trials in the UK

April 2, 2020

Gilead has initiated two phase 3 clinical trials in the UK to test remdesivir for treatment of patients with COVID-19.

The two studies will initially involve 15 centers in the UK and will evaluate the antiviral’s safety and efficacy in moderate to severe COVID-19 patients.

Clinical trials of remdesivir are currently under way around the world, including in the U.S. Remdesivir is also included as one arm of the World Health Organization’s SOLIDARITY trial.

View today's stories